Metabolic control analysis in drug discovery and disease
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 1×
“Targets for cancer therapies Tumor cells are characterized by a high rate of glucose turnover and rapid proliferation, which must be a consequence of changes in the expression of numerous metabolic enzymes involved in glucose oxidation or anabolic glucose us”
BackgroundApplied Multivariate Statistical Analysis.
Johnson, A. R., & Wichern, D. W. (1988) · Biometrics · doi:10.2307/2531616 · Cited by 11,353
The chromosomes in human cancer and leukemia
Sandberg, A. A. (1990) · Medical Entomology and Zoology · Cited by 1,753
Applied Multivariate Statistical Analysis
Ziegel, E. R., Johnson, R. A., & Wichern, D. W. (1999) · Technometrics · doi:10.2307/1271011 · Cited by 1,547
Understanding the control of metabolism
(1997) · Choice Reviews Online · doi:10.5860/choice.34-6252 · Cited by 1,231
Oncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
THE MOLECULAR BASIS OF DOMINANCE
Kacser, H., & Burns, J. A. (1981) · Genetics · doi:10.1093/genetics/97.3-4.639 · Cited by 1,029
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005
The applications of PET in clinical oncology.
Strauss, L. G., & Conti, P. S. (1991) · PubMed · Cited by 844
WARBURN, O., & DICKENS, F. (1931) · The American Journal of the Medical Sciences · doi:10.1097/00000441-193107000-00022 · Cited by 808
Research works printed but not linked: 11
- Voit E.O. Computational analysis of biochemical systems (Cambridge University Press, Cambridge, 2000).
- Cornish-Bowden, A. & Eisenthal, R. Prospects for pharmacological manipulation of metabolism. in New beer in an old bottle (ed. Cornish-Bowden, A.) 215–224 (Universitat de Valencia, Spain, 1997).
- Salter, M., Knowles, R.G. & Pogson, C.I. Metabolic control. Essays Biochem. 28, 1–12 (1994).
- Rohwer, J.M., Schuster, S. & Westerhoff, H.V. How to recognize monofunctional units in a metabolic system. J. Theoret. Biol. 179, 213–228 (1996). · doi:10.1006/jtbi.1996.0062
- Hollán, S. et al. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers, one with and one without neurological symptoms. Hum. Genet. 92, 486–490 (1993). · doi:10.1007/bf00216456
- Mitelman, F. Catalogue of chromosome aberrations in cancer (Wiley-Liss, New York, 1994).
- Bauer K.H. Das Krebsproblem, Edn. 1 (Springer, Berlin, Göttingen and Heidelberg, 1963). · doi:10.1007/978-3-642-86062-1
- Krebs., E.T. Jr., Krebs, E.T. Sr. & Beard, H.H. The unitarian or trophoblastic thesis of cancer. Med. Record 163, 150–171 (1950).
- Raylman, R.R., Fisher, S.J., Brown, R.S., Ethier, S.P. & Wahl, R.L. Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. J. Nuclear Med. 36, 1869–1874 (1995).
- Michels, P.A. Compartmentation of glycolysis in trypanosomes: a potential target for new trypanocidal drugs. Biol. Cell 64, 157–164 (1988). · doi:10.1016/0248-4900(88)90075-5
- Kacser, H. & Small, J.R. How many phenotypes from one genotype? The case of Prion diseases. J. Theor. Biol. 182, 209–218 (1996). · doi:10.1006/jtbi.1996.0157
Cited by
Computational systems biology.
Kitano, H. (2002) · Nature · doi:10.1038/nature01254 · Cited by 2,209
The emerging field of lipidomics
Wenk, M. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1776 · Cited by 1,330
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Statistical strategies for avoiding false discoveries in metabolomics and related experiments
Broadhurst, D. I., & Kell, D. B. (2007) · Metabolomics · doi:10.1007/s11306-006-0037-z · Cited by 817
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
“How should we develop multi-target drugs? In recent years several experimental and modeling approaches have been developed to identify single targets in a network context [20-22,25-33].”
BackgroundMethodNutrigenomics: goals and strategies
Müller, M., & Kersten, S. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1047 · Cited by 643
Hosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R., & Vander Heiden, M. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.02.012 · Cited by 641
Metabolomics and systems biology: making sense of the soup
KELL, D. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.04.012 · Cited by 529
“[8 ,49,50]).”
Cancer: A Systems Biology disease
Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., & Lankelma, J. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.05.014 · Cited by 381
“Answering such questions is of vital importance not only for our understanding of these complex cellular systems, but also for drug design, since it allows for the identification of drug targets according to the magnitude of their control on cell pathology (Cascante et al., 2002).”
BackgroundAssignment of Endogenous Substrates to Enzymes by Global Metabolite Profiling
Saghatelian, A., Trauger, S. A., Want, E. J., Hawkins, E. G., Siuzdak, G., & Cravatt, B. F. (2004) · Biochemistry · doi:10.1021/bi0480335 · Cited by 316
Shestov, A. A., Liu, X., Ser, Z., Cluntun, A. A., Hung, Y. P., Huang, L., Kim, D., Le, A., Yellen, G., Albeck, J. G., et al. (2014) · eLife · doi:10.7554/elife.03342 · Cited by 315
Systems biology in cardiovascular disease: a multiomics approach
Joshi, A., Rienks, M., Theofilatos, K., & Mayr, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00477-1 · Cited by 301
Systems biology, metabolic modelling and metabolomics in drug discovery and development
Kell, D. B. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.004 · Cited by 297
NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations
Emwas, A.-H. M., Salek, R. M., Griffin, J. L., & Merzaban, J. (2013) · Metabolomics · doi:10.1007/s11306-013-0524-y · Cited by 296
Metabolomics applications of FT‐ICR mass spectrometry
Brown, S. C., Kruppa, G., & Dasseux, J. (2005) · Mass Spectrometry Reviews · doi:10.1002/mas.20011 · Cited by 286
Ortmayr, K., Dubuis, S., & Zampieri, M. (2019) · Nature Communications · doi:10.1038/s41467-019-09695-9 · Cited by 142
Gjedde, A., Kumakura, Y., Cumming, P., Linnet, J., & Møller, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912319107 · Cited by 130
The Stable Isotope-based Dynamic Metabolic Profile of Butyrate-induced HT29 Cell Differentiation
Boren, J., Lee, W.-N. P., Bassilian, S., Centelles, J. J., Lim, S., Ahmed, S., Boros, L. G., & Cascante, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302932200 · Cited by 78
Self-citationAmoedo, N. D., Obre, E., & Rossignol, R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.02.005 · Cited by 76
Choudhury, S., Narayanan, B., Moret, M., Hatzimanikatis, V., & Miskovic, L. (2024) · Nature Catalysis · doi:10.1038/s41929-024-01220-6 · Cited by 67
Plant Metabolic Modeling: Achieving New Insight into Metabolism and Metabolic Engineering
Baghalian, K., Hajirezaei, M.-R., & Schreiber, F. (2014) · The Plant Cell · doi:10.1105/tpc.114.130328 · Cited by 63
Human metabolic network reconstruction and its impact on drug discovery and development
Ma, H., & Goryanin, I. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.002 · Cited by 59
“39 Cascante, M. et al. (2002) Metabolic control analysis in drug discovery and disease.”
BackgroundA new strategy for assessing sensitivities in biochemical models
Sahle, S., Mendes, P., Hoops, S., & Kummer, U. (2008) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2008.0108 · Cited by 44
Somvanshi, P. R., Mellon, S. H., Flory, J. D., Abu-Amara, D., PTSD Systems Biology Consortium;, Wolkowitz, O. M., Yehuda, R., Jett, M., Hood, L., Marmar, C., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00065.2019 · Cited by 43
Advanced stoichiometric analysis of metabolic networks of mammalian systems
Orman, M. A., Berthiaume, F., Androulakis, I. P., & Ierapetritou, M. G. (2011) · Critical Reviews™ in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v39.i6.30 · Cited by 32
Exploration of Quantitative Scoring Metrics to Compare Systems Biology Modeling Approaches
Kaddi, C., Oden, E. D., Quo, C. F., & Wang, M. D. (2007) · 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society · doi:10.1109/iembs.2007.4352493 · Cited by 5
“Four established modeling approaches were selected for analysis and comparison: (i) Michaelis-Menten kinetics (MM) [4]-[7], (ii) General Mass Action (GMA) [5]-[6], (iii) Flux Balance Analysis (FBA) [5]-[6], [8] and (iv) Metabolic Control Analysis (MCA) [5]-[6], [9]-[10].”
Method
Metadata
- Authors
- Cascante, M., Boros, L. G., Comin-Anduix, B., de Atauri, P., Centelles, J. J., & Lee, P. W.-N.
- Venue
- Nature Biotechnology
- Published
- 2002-03
- Volume
- 20
- Issue
- 3
- Pages
- 243-249
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2008715595
- Cited by
- 281
- References
- 62
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.